Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
Date:8/8/2011

9.2 million, or $0.16 per share, for the comparable period in 2010, representing an increase in net loss of $0.3 million.  The six months ended June 30, 2011 included the $5.0 million milestone payment discussed above. Other research and development expenses, for the six months ended June 30, 2011, increased by $5.2 million principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the six months ended June 30, 2011, included $1.1 million of non-cash compensation expense related to equity incentive grants.

Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, said, "During the quarter, we made significant progress in our Phase 3 programs.  With the announcement last week of completion of enrollment into our Perifosine Phase 3 program in advanced refractory colorectal cancer, we are only several months away from the completion of this important study.  On Zerenex, we were proud to have our Phase 3 short-term data presented in an oral presentation at the NKF annual meeting, as we continue to move forward with the long-term study."  Mr. Bentsur continued, "On the financial side, solidifying our balance sheet with the $33 million registered offering, we believe we are well capitalized to execute on our business plan."

The Company will host an investor conference call today, Monday, August 8, 2011, at 8:30am EDT, to discuss the Company's second quarter financial results and provide a business outlook for the remainder of 2011.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commerci
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
3. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
4. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
7. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
10. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
11. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Oct. 24, 2014  Heska Corporation (Nasdaq: ... You to Join Its Third Quarter 2014 Earnings Conference ... a.m. (MDT) / 11:00 a.m. (EDT)Where: , www.heska.com ... on the front page of this website)How:Live over the ... the address above.  Alternatively, you may use the following ...
(Date:10/25/2014)... , Oct. 24, 2014  The National Association ... latest results achieved by Kentucky,s ... The National Precursor Log Exchange (NPLEx) ... point of sale and helps flag meth offenders ... often set up NPLEx "watch lists" that notify ...
(Date:10/25/2014)... 2014   Metanome, Inc. , a ... data analysis, was the genomic sequencing provider for Seres ... clinical trial of SER 109, an Ecobiotic® therapeutic for ... infections (CDI). Metanome has provided genomic ... clinical programs. Such genomic characterization has enabled the study ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2
... 2, 2012  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Marketing Authorization Application (MAA) with the European Medicines Agency ... weight control, including weight loss and maintenance of weight ... patients who are overweight (BMI >27) and have at ...
... 2012 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... leading specialty hospital management solution provider and operator ... imaging centers in China, today announced it will release ... full year 2011 after the market closes, at ...
Cached Medicine Technology:Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 2Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 3Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 4Concord Medical to Report Fourth Quarter and Full Year 2011 Financial Results on March 21, 2012 2
(Date:10/25/2014)... (PRWEB) October 25, 2014 Background: , ... Recovery (CCAR). He is a pioneer in the field of ... in Connecticut's state treatment system and when he retired, he ... him while in public service. , 1. ... critical decisions concerning them? , 2. Can the recovery ...
(Date:10/25/2014)... 25, 2014 Market Research ... Industry, 2009-2019 is a professional and in-depth ... Diagnostics industry. The report firstly reviews the ... classification, application and manufacturing technology. The report ... of Molecular Diagnostics listing their product specification, ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... Researchers who discovered antibiotics in farmed and wild ... The use of antibiotics in animals, including ... to the development of antibiotic-resistant bacteria that threaten ... study. Each year in the United States, ... kill about 23,000, according to the Infectious Diseases ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... is not a luxury;,it is an activity that is ... survey analysis of 30 companies and in-depth interviews,with seven ... in a,difficult economy., The complete study addresses areas ... goals of benchmarking studies, how companies are,demonstrating value through ...
... chemical serotonin influences fat metabolism , , THURSDAY, June 5 ... a frustrating truism familiar to the diet-conscious choosing between ... weight control isn,t just a matter of what you ... system is genetically predisposed to process fat. , The ...
... Forum to Explore Solutions Presented by The Massachusetts ... 5 "We are greatly,concerned in this state about ... of our returning veterans, the stress, depression and ... specter of rising levels of,domestic violence and suicide. ...
... The U. S. Army Corps of,Engineers, in partnership ... and recreation industry partners, will,participate in the first ... On this day, more than 75 organizations will ... privately-managed recreation sites,across the country according to event ...
... and ... more, ... and figure competitors Allison,Frahn and Tina Durkin, will represent GNC at the ... in Atlanta., Chad, part of the World Natural Bodybuilding Federation (WNBF), ...
... top equine veterinarians perform leading-edge techniques and,identify ... lives of both,horses and humans, WASHINGTON, ... Research (FBR) releases its feature film Majestic ... Dr. Larry Bramlage (Rood & Riddle,Equine Hospital) ...
Cached Medicine News:Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2Health News:Weight Gain May Not Be Based Just on What You Eat 2Health News:Weight Gain May Not Be Based Just on What You Eat 3Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:Army Corps of Engineers Will Host National Get Outdoors Day Activities at Six Corps Project Sites 2Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2Health News:The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere 2